Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study

Shinichiro Okamoto, S. Takahashi, Ryuji Tanosaki, H. Sakamaki, Y. Onozawa, H. Oh, S. Miyawaki, Y. Kimura, K. Toyama, Y. Ikeda, S. Asano

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist, with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation. Fifty-eight patients were evaluable for analysis. The number of emetic episodes expressed in terms of patient-days was significantly lower in the granisetron group than in the control group (P < 0.001). During the first 24 h of conditioning, 27 of the 31 patients (87.1%) in the granisetron group achieved control of emesis with less than three emetic episodes (major a) a day compared with 37.0% in the control group (P < 0.001). The same degree of emesis control was maintained throughout the conditioning period in 51.0% of patients in the granisetron group compared with 0% in the control group (P < 0.001). Adverse reactions were observed in 11.4% of patients in the granisetron group and in 25.9% in the control group. None of the events were serious. Based on these data, we conclude that granisetron is superior to standard antiemetics in protecting against the vomiting induced by conditioning for stem cell transplantation.

Original languageEnglish
Pages (from-to)679-683
Number of pages5
JournalBone Marrow Transplantation
Volume17
Issue number5
Publication statusPublished - 1996 May

Fingerprint

Granisetron
Stem Cell Transplantation
Vomiting
Prospective Studies
Control Groups
Emetics
Antiemetics
Receptors, Serotonin, 5-HT3
Metoclopramide

Keywords

  • Bone marrow transplantation
  • Conditioning
  • Granisetron
  • Total body irradiation
  • Vomiting

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation : A prospective randomized study. / Okamoto, Shinichiro; Takahashi, S.; Tanosaki, Ryuji; Sakamaki, H.; Onozawa, Y.; Oh, H.; Miyawaki, S.; Kimura, Y.; Toyama, K.; Ikeda, Y.; Asano, S.

In: Bone Marrow Transplantation, Vol. 17, No. 5, 05.1996, p. 679-683.

Research output: Contribution to journalArticle

Okamoto, S, Takahashi, S, Tanosaki, R, Sakamaki, H, Onozawa, Y, Oh, H, Miyawaki, S, Kimura, Y, Toyama, K, Ikeda, Y & Asano, S 1996, 'Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study', Bone Marrow Transplantation, vol. 17, no. 5, pp. 679-683.
Okamoto, Shinichiro ; Takahashi, S. ; Tanosaki, Ryuji ; Sakamaki, H. ; Onozawa, Y. ; Oh, H. ; Miyawaki, S. ; Kimura, Y. ; Toyama, K. ; Ikeda, Y. ; Asano, S. / Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation : A prospective randomized study. In: Bone Marrow Transplantation. 1996 ; Vol. 17, No. 5. pp. 679-683.
@article{824e319ff4e5480ab9bf05d428e4aa40,
title = "Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study",
abstract = "We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist, with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation. Fifty-eight patients were evaluable for analysis. The number of emetic episodes expressed in terms of patient-days was significantly lower in the granisetron group than in the control group (P < 0.001). During the first 24 h of conditioning, 27 of the 31 patients (87.1{\%}) in the granisetron group achieved control of emesis with less than three emetic episodes (major a) a day compared with 37.0{\%} in the control group (P < 0.001). The same degree of emesis control was maintained throughout the conditioning period in 51.0{\%} of patients in the granisetron group compared with 0{\%} in the control group (P < 0.001). Adverse reactions were observed in 11.4{\%} of patients in the granisetron group and in 25.9{\%} in the control group. None of the events were serious. Based on these data, we conclude that granisetron is superior to standard antiemetics in protecting against the vomiting induced by conditioning for stem cell transplantation.",
keywords = "Bone marrow transplantation, Conditioning, Granisetron, Total body irradiation, Vomiting",
author = "Shinichiro Okamoto and S. Takahashi and Ryuji Tanosaki and H. Sakamaki and Y. Onozawa and H. Oh and S. Miyawaki and Y. Kimura and K. Toyama and Y. Ikeda and S. Asano",
year = "1996",
month = "5",
language = "English",
volume = "17",
pages = "679--683",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation

T2 - A prospective randomized study

AU - Okamoto, Shinichiro

AU - Takahashi, S.

AU - Tanosaki, Ryuji

AU - Sakamaki, H.

AU - Onozawa, Y.

AU - Oh, H.

AU - Miyawaki, S.

AU - Kimura, Y.

AU - Toyama, K.

AU - Ikeda, Y.

AU - Asano, S.

PY - 1996/5

Y1 - 1996/5

N2 - We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist, with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation. Fifty-eight patients were evaluable for analysis. The number of emetic episodes expressed in terms of patient-days was significantly lower in the granisetron group than in the control group (P < 0.001). During the first 24 h of conditioning, 27 of the 31 patients (87.1%) in the granisetron group achieved control of emesis with less than three emetic episodes (major a) a day compared with 37.0% in the control group (P < 0.001). The same degree of emesis control was maintained throughout the conditioning period in 51.0% of patients in the granisetron group compared with 0% in the control group (P < 0.001). Adverse reactions were observed in 11.4% of patients in the granisetron group and in 25.9% in the control group. None of the events were serious. Based on these data, we conclude that granisetron is superior to standard antiemetics in protecting against the vomiting induced by conditioning for stem cell transplantation.

AB - We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist, with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation. Fifty-eight patients were evaluable for analysis. The number of emetic episodes expressed in terms of patient-days was significantly lower in the granisetron group than in the control group (P < 0.001). During the first 24 h of conditioning, 27 of the 31 patients (87.1%) in the granisetron group achieved control of emesis with less than three emetic episodes (major a) a day compared with 37.0% in the control group (P < 0.001). The same degree of emesis control was maintained throughout the conditioning period in 51.0% of patients in the granisetron group compared with 0% in the control group (P < 0.001). Adverse reactions were observed in 11.4% of patients in the granisetron group and in 25.9% in the control group. None of the events were serious. Based on these data, we conclude that granisetron is superior to standard antiemetics in protecting against the vomiting induced by conditioning for stem cell transplantation.

KW - Bone marrow transplantation

KW - Conditioning

KW - Granisetron

KW - Total body irradiation

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=9344231964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344231964&partnerID=8YFLogxK

M3 - Article

C2 - 8733681

AN - SCOPUS:9344231964

VL - 17

SP - 679

EP - 683

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -